precipio diagnostics and transgenomic complete merger  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street precipio diagnostics and transgenomic complete merger business wire jun    am edt precipio diagnostics llc and transgenomic inc otcqb tbiod today announced the closing of their previously announced merger in connection with the transaction transgenomic has changed its name to precipio inc precipios common stock is expected to commence trading on the nasdaq stock market under the new ticker symbol prpo upon the opening of trading on june   or soon thereafter the company will operate under the leadership of ilan danieli chief executive officer carl iberger chief financial officer and steve miller chief commercial officer the board of directors of precipio will initially be comprised of five directors robert patzig will remain as chairman of the board together with michael luther one of transgenomics existing board members samuel riccitelli mark rimer and ilan danieli together comprise the remaining members of the board precipios corporate headquarters is in new haven connecticut the union of precipio and transgenomic enables us to fulfill our vision of a worldclass innovative company dedicated to eradicating the pervasive problem of disease misdiagnosis said ilan danieli ceo of precipio we believe that the combination of precipio and transgenomic can transform medical care by leveraging precipios unique diagnostic platform with transgenomics enabling technology for dna liquid biopsies to deliver better and more accurate diagnostic information to physicians and their patients worldwide terms of the merger include the initial closing on a  million private placement of preferred and convertible securities out of a total authorized amount of up to  million in preferred equity simultaneous with the merger holders of more than  million in secured debt have converted into equity providing the combined company with a stronger balance sheet completion of our merger marks an exciting new chapter in the history of our companies precipio and transgenomics teams have already accomplished a great deal in our shared drive to ensure that the new precipio is primed for growth we look forward to sharing more details on our plans and milestones in the coming weeks mr danieli concluded trending amazons shock earnings show that its cashing in on wall streets goodwill amazon falls obamacare repeal fails   things you must know before the market opens ftc seen as set to block rite aid deal these are our  biggest stories on amazons bizarre earnings whiff  foods to avoid if you have high cholesterol advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers legal hemepath               smartgentm          smartpathtm join our network login test requisition form click here legal  disclaimer this website is provided “as is” without any representations or warranties express or implied precipio diagnostics makes no representations or warranties in relation to this website or the information and materials provided on this website without prejudice to the generality of the foregoing paragraph precipio diagnostics does not warrant that this website will be constantly available or available at all or that the information on this website is complete true accurate or nonmisleading nothing on this website constitutes or is meant to constitute advice of any kind if you require advice in relation to any legal financial or medical matter you should consult an appropriate professional   limitations of liability precipio diagnostics will not be liable to you whether under the law of contact the law of torts or otherwise in relation to the contents of or use of or otherwise in connection with this website to the extent that the website is provided freeofcharge for any direct loss for any indirect special or consequential loss or for any business losses loss of revenue income profits or anticipated savings loss of contracts or business relationships loss of reputation or goodwill or loss or corruption of information or data these limitations of liability apply even if precipio diagnostics has been expressly advised of the potential loss   exceptions nothing in this website disclaimer will exclude or limit any warranty implied by law that it would be unlawful to exclude or limit and nothing in this website disclaimer will exclude or limit precipio diagnostics’ liability in respect of any death or personal injury caused by precipio diagnostics’ negligence fraud or fraudulent misrepresentation on the part of precipio diagnostics or any matter which it would be illegal or unlawful for precipio diagnostics to exclude or limit or to attempt or purport to exclude or limit its liability   reasonableness by using this website you agree that the exclusions and limitations of liability set out in this website disclaimer are reasonable if you do not think they are reasonable you must not use this website   other parties you accept that as a limited liability entity precipio diagnostics has an interest in limiting the personal liability of its officers and employees you agree that you will not bring any claim personally against precipio diagnostics’ officers or employees in respect of any losses you suffer in connection with the website without prejudice to the foregoing paragraph you agree that the limitations of warranties and liability set out in this website disclaimer will protect precipio diagnostics’ officers employees agents subsidiaries successors assigns and subcontractors as well as precipio diagnostics   back to top  about vision team accreditations news careers our values ethics environment billing research contact international locations contactprecipiodxcom tel  fax   science park new haven ct  usa   pay my bill georgia india israel singapore southeast asia ukraine united arab emirates privacy  legal   precipio diagnostics all rights reserved social facebook linkedin hemepath hemepath               smartgentm          smartpathtm join our network login test requisition form click here precipio has developed in collaboration with yale faculty a proprietary process which incorporates various technologies methodologies specimen treatment techniques and other work processes omnia™ provides the following benefits the benefits of omnia™ are high level of diagnostic accuracy efficient specimen utilization to ensure availability for all necessary testing smart utilization of technology reducing average bill accuracy efficiency cost we’ve taken a unique approach that drove the development of omnia™ which balances the following philosophies    • comprehensive assessment  going beyond merely answering the clinical question to conduct a comprehensive analysis of the      patient situation  • specimen efficiency  employ intelligent specimen utilization by selecting the necessary tests in an algorithmic manner     to ensure maximum  information  • cost reduction  reduce diagnostic costs by avoiding unnecessary tests while ensuring all clinical avenues are assessed back to top  to view a sample report please click here about vision team accreditations news careers our values ethics environment billing research contact international locations contactprecipiodxcom tel  fax   science park new haven ct  usa   pay my bill georgia india israel singapore southeast asia ukraine united arab emirates privacy  legal   precipio diagnostics all rights reserved social facebook linkedin accreditations hemepath               smartgentm          smartpathtm join our network login test requisition form click here precipio is accredited by the following associations clia   precipio can receive specimens from physicians practicing in the following states   alabama alaska arizona arizona arkansas california colorado connecticut delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico north carolina north dakota ohio oklahoma oregon pennsylvania south carolina south dakota tennessee texas utah vermont virginia washington west virginia wisconsin wyoming back to top  about vision team accreditations news careers our values ethics environment billing research contact international locations contactprecipiodxcom tel  fax   science park new haven ct  usa   pay my bill georgia india israel singapore southeast asia ukraine united arab emirates privacy  legal âš  precipio diagnostics all rights reserved social facebook linkedin test requisition hemepath               smartgentm          smartpathtm join our network login test requisition form click here please click below to download our printable requisition form     hematologyoncology requisition surgical requisition smartgen™ requisition smartpath™ nd opinion consult requisition back to top  about vision team accreditations news careers our values ethics environment billing research contact international locations contactprecipiodxcom tel  fax   science park new haven ct  usa   pay my bill georgia india israel singapore southeast asia ukraine united arab emirates privacy  legal   precipio diagnostics all rights reserved social facebook linkedin join our network hemepath               smartgentm          smartpathtm join our network login test requisition form click here join our network back to top  about vision team accreditations news careers our values ethics environment billing research contact international locations contactprecipiodxcom tel  fax   science park new haven ct  usa   pay my bill georgia india israel singapore southeast asia ukraine united arab emirates privacy  legal âš  precipio diagnostics all rights reserved social facebook linkedin singapore hemepath               smartgentm          smartpathtm back to top  singapore   asia tmt  robinson road  far east finance building singapore  tel  fax  email matthewaujlaasiatmtnet test requisition form click here join our network login about vision team accreditations news careers our values ethics environment billing research contact international locations contactprecipiodxcom tel  fax   science park new haven ct  usa   pay my bill georgia india israel singapore southeast asia ukraine united arab emirates privacy  legal âš  precipio diagnostics all rights reserved social facebook linkedin home hemepath               smartgentm          smartpathtm test requisition form click here join our network login democratizing diagnostics connecting physicians and their patients with the highest level of diagnostic expertise to battle cancer connecting physicians and their patients with the highest level of diagnostic expertise to battle cancer democratizing diagnostics the problem delivering a correct diagnosis requires increased skill expertise and specialization the economic forces within the world of diagnostics continue to drive the market towards generalization and away from specialization this results in the alarmingly growing and largely ignored problem of misdiagnosis generalization specialization back to top  the consequences of misdiagnosis patient suffering  death absent proper diagnostic support physicians are handicapped in delivering the best care to their patients significant downstream healthcare dollars wasted estimated at b annually in the us in order to avoid these consequences physicians need access to expertise from specialists rather than generalists we have the expertise we’ve harnessed the best resources within leading academic institutions and we deliver them to support community clinicians we give physicians access to the expertise they require to support the care for their patients we engage patients in the process and enable them to influence their healthcare decisions we translate the expertise and technology developed at academic institutions to benefit those outside its walls with the combination of academic expertise and the translation of this expertise to the community setting precipio has demonstrated a significantly superior level of diagnostic accuracy weve achieved groundbreaking diagnostic accuracy in the past four years we’ve diagnosed over  cases sent to us by community oncologists from around the world and weve demonstrated an  level of diagnostic accuracy industry precipio   correct diagnosis  correct diagnosis  misdiagnosis  misdiagnosis   based on several industry studies including the  report by the institute of health and the  study by the national coalition of health care  based on an initial data set of over  clinical cases diagnosed at precipio with a nd opinion then conducted at an outside institution interested in learning more click here to join our network about vision team accreditations news careers our values ethics environment billing research contact international locations contactprecipiodxcom tel  fax   science park new haven ct  usa   pay my bill georgia india israel singapore southeast asia ukraine united arab emirates privacy  legal   precipio diagnostics all rights reserved social facebook linkedin precipio diagnostics llc credit report products contacts florida search precipio diagnostics llc company number m status active fei number  company type foreign limited liability home state de last activity date not available date of incorporation  principal address  science park rd floor new haven  mailing address  science park rd floor new haven ct  precipio diagnostics llc principals chairman e o danieli ben address  science park rd floor new haven ct  chairman f o alon gil address  science park rd floor new haven ct  registered agent agent name c t corporation system c agent address  south pine island road plantation fl  precipio diagnostics llc events  revoked for annual report fileddate  description precipio diagnostics llc has been set up  in state de the current status of the business is active the precipio diagnostics llc principal adress is  science park rd floor new haven  meanwhile you can send your letters to  science park rd floor new haven ct  the companys registered agent is c t corporation system  south pine island road plantation fl  the companys management are chairman e o  danieli ben chairman f o  alon gil the last significant event in the company history is revoked for annual report which is dated by  this decision is take in action on unknown comprehensive report about this company view sample similar companies precipitating ministries inc precipitation control systems inc precipitator maintenance corp precipitator services group inc precip llc precipuo enterprises inc precipio diagnostics llc  company profile  biocentury publications archives bciq conferences version  free trial  subscribe sign in english   한국어 biocentury menu home  publications  publications home  biocentury bc innovations bc extra bc week in review current issues archives  archives home  basic search advanced search back issues bciq  bciq home  overview pipeline analyst financial analyst company analyst deal analyst conferences  conferences home  newsmakers bio€quity europe future leaders china healthcare summit other industry events elearning  elearning home  videos white papers follow us bciq  company profile bciq overview      settings      support biocentury print this       precipio diagnostics llc not active print preview export bookmark share with colleague general information  location new haven conn  region new england  country us  business category diagnostic supplyservice  year founded  website httpwwwprecipiodxcom  lead product status na  history more  archive items are loading  financial information  financing summary  financing details  earnings summary  stocks annual chart  pipeline information  pipeline summary  pipeline details  deals information  deals summary  deals details about biocentury company overview management editorial  research contact contact us advertising  sponsorship career opportunities support forgot password customer service reprints faqs products  solutions products overview publications archives bciq conferences elearning rss feeds legal user agreement terms of use privacy policy your california privacy rights use of images follow us what is biocentury biocentury employs a fully integrated multimedia platform — including publications video online data solutions and conferences — to provide its audience with authoritative and uptodate intelligence about corporate strategy partnering emerging technology clinical data public policy and the financial markets sign in free trial   biocentury inc all rights reserved    terms  conditions  privacy policy set email alert dummy microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft transgenomic stockholders and precipio diagnostics members approve mergerhomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets open in  hrs  minssp futures dow futures nasdaq futures transgenomic stockholders and precipio diagnostics members approve mergerbusiness wirejune  reblogsharetweetshareomaha neb  new haven connbusiness wiretransgenomic inc tbio today announced that its stockholders have approved the merger with precipio diagnostics llc upon completion of the merger the company expects to meet the requirements for its stock to be relisted on nasdaq under the new symbol “prpo”over  of the votes cast by transgenomic shareholders were in favor of the merger and the other various proposals that were put forth for consideration at yesterday’s special stockholder meeting in addition precipio diagnostics’ members approved the merger with over  of the outstanding membership interests voting in favor both companies are continuing to work to close the combined company’s  million private placement of preferred convertible securities as well as a conversion of all outstanding secured debt into the combined company’s preferred convertible securitiesupon completion of these remaining conditions the merger will be consummated additionally the conversion of secured debt and planned capital infusion are expected to provide the combined company with a clean balance sheet and sufficient capital to pursue its planned expansionpaul kinnon transgenomic president and chief executive officer said “we are very pleased that the merger with precipio has been approved by the stakeholders in both companies we believe that the combination of our leading ice coldpcr mutation detection technology and precipio diagnostics’ unique business model and expertise aimed at improving the diagnosis and treatment of cancer has major clinical and commercial potential”“we are delighted to have reached this stage and received the approval of both companies’ stockholders and members for the merger we appreciate everyone’s patience as the companies went through this long and complex process and now we are ready to get to work and focus together on building the new company” said ilan danieli precipio diagnostics founder and chief executive officer “we believe strongly that this is the beginning of increased value creation for our stockholders and new investors as we join these two companies’ business models and teams utilizing our network of expertise and proprietary technologies to deliver an improved level of diagnostic accuracy to patients”transgenomic’s ice coldpcr icp offers major advantages over current sequencing technologies it delivers at least a fold improvement in sensitivity compared to standard methodologies allowing detection of both known and previously unknown genetic alterations in any exon of any gene using a single assay it is robust easy to use and easily implemented requiring minimal disruption to established sequencing workflows icp technology is available as iceme™ kits that deliver up to a fold increase in mutation detection compared to most current methods with levels of detection routinely achievable down to  this ultrahigh sensitivity enables detection of low level mutations that allow accurate patient monitoring as well as stratification of cancer subpopulations iceme kits work well with most patient samples including tissue blood plasma urine and other biofluids the kits are simple to use and work with most of the genomic analytic platforms available in laboratories today they are easily customizable for use with single mutations or in combination the current menu includes approximate  clinically relevant actionable mutations that are associated with important cancers additional mutations are being added on an ongoing basisice coldpcr was originally developed by the laboratory of dr mike makrigiorgos at the danafarber cancer institute which has exclusively licensed rights to the technology to transgenomicabout transgenomictransgenomic inc is a global biotechnology company advancing personalized medicine in oncology and inherited diseases through advanced diagnostic technologies such as its revolutionary ice coldpcr which enables use of liquid biopsies for mutation detection the company also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomesread moreabout precipio diagnosticsprecipio diagnostics has built a platform to harness the intellect expertise and technology developed within academia delivering quality diagnostic information to physicians and patients worldwide through its collaborations with worldclass academic institutions specializing in cancer research diagnostics and treatment and its experience delivering quality service precipio diagnostics offers a new standard of diagnostic accuracy enabling the highest level of patient care for more information visit precipiodxcomforwardlooking statementscertain statements in this press release constitute “forwardlooking statements” which involve known and unknown risks uncertainties and other factors that may cause actual results to be materially different from any future results performance or achievements expressed or implied by such statements forwardlooking statements include but are not limited to those with respect to managements current views and estimates of future economic circumstances industry conditions company performance and financial results including the ability of the company to grow its involvement in the diagnostic products and services markets expectations regarding new clients projects and prospects and icp’s ability to accelerate the company’s growth and generate revenue the known risks uncertainties and other factors affecting these forwardlooking statements are described from time to time in transgenomics filings with the securities and exchange commission any change in such factors risks and uncertainties may cause the actual results events and performance to differ materially from those referred to in such statements all information in this press release is as of the date of the release and transgenomic does not undertake any duty to update this information including any forwardlooking statements unless required by lawview source version on businesswirecom httpwwwbusinesswirecomnewshomeenreblogsharetweetsharerecently viewedyour list is emptywhat to read nextangelina jolie opens up about brad pitt divorce and reveals bells palsy diagnosisthe telegraphthis will be in everyones household by banyan hillsponsoredsean hannity responds to claim he ran up a  tab at trumps hotel after flying in a yearold lobster from mainebusiness insidermattis was on vacation when trump tweeted transgender ban and he was reportedly appalled by itbusiness insidertrump’s unwitting legacy could be universal health coverageyahoo financezuckerberg wifes ambitious secret finally exposedunewzmesponsoredvirgin atlantic founder sir richard branson sells pc stake in airline for £m as part of new tieup with air franceklmthe telegraphtwitter is only famous now because of president trump nyse traderyahoo finance videogdp — what you need to know in markets on fridayyahoo financeengineer finds pattern makes millions in stocksmoney morningsponsoredrepublicans kill the border taxyahoo financeamazon wobble creates ripples across worldwide stock marketsreutersa pga tour pro explained what separates jordan spieth from fellow stars like rory mcilroy and dustin johnsonbusiness insidermarisa tomei finally confirms the rumorskiwi reportsponsoredverizon q revenue flat as wireless unit sales decline  despite subcriber reboundvarietyamazon could be the first trillion dollar company nyse traderyahoo finance videoboy scouts chief apologizes for donald trumps politically charged speechgordon it is pathetic that trump cannot even pretend he is a decent person and make a speach about good citizenship he has to talk about how people are unfair to him what a repulsive little person he is i am embarrassed for my countryjoin the conversation   precipio diagnostics llc company profile  bloomberg feedback precipio diagnostics llc private company company profile sector health care industry medical equipment  devices subindustry life science equipment precipio diagnostics llc operates as a cancer diagnostics reference laboratory the company delivers diagnostics and personalized medicine and other medicinal solutions precipio diagnostics markets to physicians throughout the united states corporate information address  science park rd floor new haven ct  united states phone  fax  web url wwwprecipiodxcom from the web sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data precipio diagnostics llc  new haven ct usa startup start up confidently with gust launch all the legal accounting and financial tools you need to start and run your company overview executive summary financials documents precipio diagnostics llc precipio harnesses the intellect expertise and technology developed within academia and delivers it to community physicians stage k in ttm revenue industry healthcare services location new haven ct usa currency usd founded september  employees  website precipiodxcom company summary precipio partners with academic institutions to bring the highest standard of pathology  diagnostics to community oncologists our customers are oncologists who are entirely reliant on pathology to guide them in treating their patients we take the expertise technology  intellectual capital often locked up within academia and after adding the proper processes and service level deliver it to physicians improving patient care team ilan danieli ceo ilan has  years of senior management and operational experience built on strong people skills and common sense previous experiences includes ceo of a cancer diagnostics lab coo of a m multinational public company and vp of operations at a multibillion dollar hedge fund working in both entrepreneurial and public company operations ilan understands people operations sales marketing finance  legal  and their interdependence gil alon cfo gil is a seasoned finance executive with over  years of experience in financing startup and health care institutions as well as corporate turnarounds and restructurings at private equity fund holds an mba from nyu and ba from ucla demetrios braddock md phd medical director dr braddock received his mdphd degree from the university of chicago was trained in anatomic pathology at the nih and has been on the faculty of yale since  where his primary clinical focus is hematopathology he is currently an associate professor of pathology at yale where he directs an independent laboratory focused on the structural elucidation of proteins and protein complexes that drive hematopoietic disorders jeffrey sklar md phd chief scientific officer dr sklar is a tenured faculty at yale university he holds a ba from haverford college an md and phd from yale university a postdoctorate fellowship in biochemistry at stanford university and a ma from harvard university dr sklar is a pioneer and one of the world leading thinkers in the area of molecular genetics he has developed several tests that are standard protocol of testing within pathology diagnostics laboratories david hudnall md associate medical director s david hudnall is professor of pathology and laboratory medicine and director of hematopathology at yale university school of medicine dr hudnall attended medical school at the medical university of south carolina in charleston sc  following his medical training dr hudnall completed his residency in anatomic and clinical pathology at the yalenew haven hospital yale university school of medicine  this training was fol gil alon advisors goodwin proctor lawyer unconfirmed teplitzky  company accountant unconfirmed previous investors kuzari capital unconfirmed friends  family investors unconfirmed loading precipio diagnostics llc  relationship science news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink precipio diagnostics llc overview in the news executives  employees board of directors paths recent transactions transaction advisors advisors  consultants clients investors precipio diagnostics llc overview date founded  headquarters  science park rd floor new haven ct  industries medical support services it consulting  services hospitals  patient services biotechnology company description precipio diagnostics llc operates as a cancer diagnostics reference laboratory it offers its customers community oncologists and hospitals access to academic institutions and has combined academiclevel excellence with the sales and marketing expertise the proper operational processes and the necessary service level standards required to deliver proper support the company was founded by ilan danieli in  and is headquartered in new haven ct website httpwwwprecipiodxcom in the news see more business wire june   precipio diagnostics and transgenomic complete merger business wire june   transgenomic prepares for planned relisting on nasdaq business wire june   transgenomic stockholders and precipio diagnostics members approve merger business wire may   transgenomic board confirms date and location of special meeting of stockholders and announces reverse stock split ratio business wire february   transgenomic provides update on its planned merger and reports change in listing status see full news coverage and complete stories with relsci professional create your news feed see more executives  employees ilan danieli founder jeffrey l sklar chief scientific officer demetrios t braddock medical director mehmed iljazi vice presidentadministrative operations ahmed zaki sabet vice presidenttechnical operations stanley david hudnall associate medical director  senior hematopathologist alexa siddon hematopathologist samuel g katz hematopathologist see our list of current and previous employees when you upgrade start my free trial ➤ see more board of directors richard alvin sandberg founder at dianon systems inc kevin t crowley managing director investments at connecticut innovations inc mark rimer director at precipio diagnostics llc see our list of current and previous board members when you upgrade start my free trial ➤ see more paths to precipio diagnostics llc precipio diagnostics llc you connections via relationship science precipio diagnostics llc sync your contacts to see how you can connect with precipio diagnostics llc start my free trial ➤ see more recent transactions details hidden transgenomic inc purchases precipio diagnostics llc from advantage capital partners details hidden precipio diagnostics llc raised money in a private placement transaction transaction advisors companies ▾ legal advisor goodwin procter llp advised on transgenomic inc purchases precipio diagnostics llc from advantage capital partners people ▾ legal advisor andrew h goodman advised on transgenomic inc purchases precipio diagnostics llc from advantage capital partners legal advisor stephen m davis advised on transgenomic inc purchases precipio diagnostics llc from advantage capital partners advisors  consultants people ▾ todd s barry former medical director at clarient inc clients companies ▾ rosetta genomics ltd  •  rehovot  ta rosetta genomics ltd provides therapeutic diagnostic product development and medical research services the company develops and commercializes new diagnostic tests based on various genomics markers including dna microrna and protein biomarkers and using various technologies including qpcr microarrays next generation sequencing and fluorescence in situ hybridization it offers proprietary microrna technologies such as rosetta cancer origin mikidney and rosettagx reveal test the company was founded by isaac bentwich on march   and is headquartered in rehovot israel investors details hidden advantage capital partners advantage capital focuses on investments in companies that develop or apply innovative technologies or approaches to products systems and services they typically invest in the communications information technology life science business services manufacturing and and energy sectors the firm may consider opportunities in other areas if their investment criteria are metadvantage capital invests in companies at all stages of development early expansion and later stageexcept seed round financings the firm looks for companies with a highly qualified and entrepreneurial management team a proprietary technology or unique product or concept an ability to achieve significant growth quickly through market penetration or market expansion the ability to produce an exceptional return on invested capital and prospects for investment liquidity within a determinable period of time initial investments typically range from  to  million larger investments are usually are staged over time based on preset milestones or subsequent financing events smaller investments may be made depending on the stage of the investment they prefer to coinvest with other experienced investment firms the firm provides both growth equity and mezzanine debt capital to companies through various structures their investments are typically structured as preferred equity securities and current or deferred pay debt instruments which are either convertible or issued with warrants details hidden ilan danieli founder at precipio diagnostics llc details hidden connecticut innovations inc ci typically invests between  and  per round into our companies our focus in on building technology and technologyenabled enterprises in connecticut in industries where connecticut has a strong position and competitive advantage to date primarily invested in software and it bioscience clean tech digital media and technologies important to advanced manufacturing such as photonics and advanced materials we actively seek preseed seed and early stage series a investments we look for components of the following three characteristics in evaluating investment opportunities each of which we believe are necessary to build extraordinary companiesmanagementmarkettechnologyci accomplishes their mission primarily by making equity investments in emerging connecticut technology companies providing essential nonfinancial support to entrepreneurs and conducting initiatives that address specific needs of connecticuts technology sector details hidden ironwood capital ironwood is an active manager which seeks to invest  to  million in leading companies providing capital to businesses through a range of transactions including growth financings full and partial recapitalizations generational transitions and buyoutsthe sectors in which they invest are information technology environmental services business services healthcare financial services and manufacturing their geographical focus is to the east of the mississippi river but go anywhere in the us for the right opportunitythey frequently take board seats and provide our insight and resources as appropriate to our management teams they provide support advice and guidance at both board and management levelsironwood has a particular interest in woman and minorityowned companies and in companies that are located in low and moderateincome areas details hidden kuzari group llc kuzari group llc operates as a private investment and strategic development firm it focuses on investing in and developing small businesses which represents longterm value creation opportunities the company was founded by benjamin gerut in  and is headquartered in new york ny see  more listing with relsci professional start my free trial ➤ see  more youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ precipio diagnostics and transgenomic complete merger  transgenomic latest presention on mxicp view the latest presentation on multiplexed ice coldpcr mxicp for detection of lowlevel mutations in any liquid biopsy sample using sanger sequencing ngs or ddpcr by katherine richardson phd vp research  development mxicp biomarker discovery patient genetic testing my account remember me cart home about us our company story our leadership our board of directors our partners our culture careers technology technology suite mxicp clinical applications oncology mxicp overview mxicp oncology tests products iceme kits iceme kits overview iceme kits details and ordering genetic assays and platforms genetic analysis kits find a genetic test biomarker discovery patient genetic testing mxicp oncology tests oncology tests specimen collection kits mxicp kits oncology kits news  events news events media investor information contact home about us our company story our leadership our board of directors our partners our culture careers technology technology suite mxicp clinical applications oncology mxicp overview mxicp oncology tests products iceme kits iceme kits overview iceme kits details and ordering genetic assays and platforms genetic analysis kits find a genetic test biomarker discovery patient genetic testing mxicp oncology tests oncology tests specimen collection kits mxicp kits oncology kits news  events news events media investor information contact precipio diagnostics and transgenomic complete merger previous precipio diagnostics and transgenomic complete merger company renamed precipio inc–to commence trading on nasdaq under the new ticker “prpo” new haven conn and omaha neb june   – precipio diagnostics llc and transgenomic inc otcqb tbiod today announced the closing of their previously announced merger in connection with the transaction transgenomic has changed its name to precipio inc precipio’s common stock is expected to commence trading on the nasdaq stock market under the new ticker symbol “prpo” upon the opening of trading on june   or soon thereafter the company will operate under the leadership of ilan danieli chief executive officer carl iberger chief financial officer and steve miller chief commercial officer the board of directors of precipio will initially be comprised of five directors robert patzig will remain as chairman of the board together with michael luther one of transgenomic’s existing board members samuel riccitelli mark rimer and ilan danieli together comprise the remaining members of the board precipio’s corporate headquarters is in new haven connecticut “the union of precipio and transgenomic enables us to fulfill our vision of a worldclass innovative company dedicated to eradicating the pervasive problem of disease misdiagnosis” said ilan danieli ceo of precipio “we believe that the combination of precipio and transgenomic can transform medical care by leveraging precipio’s unique diagnostic platform with transgenomic’s enabling technology for dna liquid biopsies to deliver better and more accurate diagnostic information to physicians and their patients worldwide” terms of the merger include the initial closing on a  million private placement of preferred and convertible securities out of a total authorized amount of up to  million in preferred equity simultaneous with the merger holders of more than  million in secured debt have converted into equity providing the combined company with a stronger balance sheet “completion of our merger marks an exciting new chapter in the history of our companies precipio and transgenomic’s teams have already accomplished a great deal in our shared drive to ensure that the new precipio is primed for growth we look forward to sharing more details on our plans and milestones in the coming weeks” mr danieli concluded over the course of the past few months in anticipation of the contemplated merger both companies have undertaken a rigorous costcutting project to reduce the combined companies’ historical burn rate postmerger management anticipates the new organization will be a leaner more capitalefficient organization these efficiencies are expected to reduce the combined entity’s operating expenses by approximately  million or more per quarter an anticipated annualized reduction of expenses of about  million compared to  the majority of the cost reductions will be achieved immediately postclosing and are related to reductions in administrative headcount and the consolidation of lab operations and facilities with a focus on eliminating redundancies and realizing efficiencies transgenomic’s omaha cliacertified laboratory operations will move to precipio’s new haven location thereby reducing the substantial costs associated with operating two fullycertified clia laboratories including but not limited to reductions in staff equipment and the total amount of leased space in addition transgenomic recently completed a move from its existing  square foot facility in omaha to a nearby smaller  square foot facility reducing facility costs by more than  the new location is wellsuited to serve as the company’s rd center to accelerate commercial activities precipio recently added a number of new salespeople to its sales team and anticipates adding more by year end the combined sales team has been crosstrained on both precipio’s pathology services and transgenomic’s ice coldpcr icp technology to enable immediate crossselling opportunities the company also intends to invest in further development of its icp technology to define specific clinical applications as well as simplifying the adaptability and implementation of icp technology for its customers paul kinnon president and ceo of transgenomic said “we believe that this merger with precipio is an excellent strategic fit for transgenomic that provides the opportunity to realize the clinical and commercial potential of our ice coldpcr technology for dna liquid biopsies within the merged company’s broad focus on precision medicine we are pleased to move forward as a combined entity to bring transformative solutions in medical diagnostics to physician and patients alike” about precipio precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide through its collaborations with worldclass academic institutions specializing in cancer research diagnostics and treatment precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care for more information visit precipiodxcom forwardlooking statements certain statements in this press release constitute “forwardlooking statements” within the meaning of federal securities laws which involve known and unknown risks uncertainties and other factors that may cause actual results to be materially different from any future results performance or achievements expressed or implied by such statements forwardlooking statements include but are not limited to those with respect to management’s current views and estimates of company performance and financial results including the ability of the company to reduce expenses and cash burn its ability to accelerate the company’s growth and generate revenue and its ability to reduce the problem of disease misdiagnosis the known risks uncertainties and other factors affecting these forwardlooking statements are described in transgenomic’s definitive proxy statement filed on may   transgenomic’s prior filings and from time to time in precipio’s subsequent filings with the securities and exchange commission any change in such factors risks and uncertainties may cause the actual results events and performance to differ materially from those referred to in such statements all information in this press release is as of the date of the release and precipio does not undertake any duty to update this information including any forwardlooking statements unless required by law contacts precipio investor relations scott gordon president core ir  oak street garden city ny  scottgcoreircom    wwwcoreircom thomas goetzingert share this story choose your platform mark rimer  director  partner at kuzari group llc news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink mark rimer director  partner at kuzari group llc overview in the news relationships paths education career history boards  committees public holdings mark rimer director  partner at kuzari group llc overview age  born  board seats  number of relationships this person is connected to  people in the news see more business wire june   precipio diagnostics and transgenomic complete merger relationships see details ilan danieli president chief executive officer  director at precipio inc michael luther former chief business development officer at the david h murdock research institute robert m patzig former senior managing director  chief investment officer at third security llc samuel d riccitelli former president  chief executive officer at miragen therapeutics inc benjamin gerut managing partner at kuzari group llc ori raam director at precipio diagnostics llc kevin t crowley managing director investments at connecticut innovations inc richard alvin sandberg founder at dianon systems inc jeffrey l sklar director molecular diagnostics program at yale university chris mcleod directorsloan school at massachusetts institute of technology see  more listings with relsci professional start my free trial ➤ see  more paths to mark rimer mark rimer you connections via relationship science mark rimer sync your contacts to see how you can connect with mark rimer start my free trial ➤ see more educational background   new york university  leonard n stern school of business since its inception in  new york university stern school of business has been in and of new york city founded as the school of commerce finance and accounting the school initially offered training to students for careers in commerce in the burgeoning financial markets of new york city today located in the heart of greenwich village with a campus in westchester stern is one of the nation’s premier management education schools and research centers with a broad portfolio of academic programs at the graduate and undergraduate levels with its global partnerships and engagement in nyu’s global network university today nyu stern is not only in and of the city but also in and of the world   university of bristol the university of bristol is a red brick research university that offers a range of educational courses and services the university is organized into six academic facilities faculty of arts faculty of engineering faculty of medical and veterinary sciences faculty of science faculty of medicine and dentistry and faculty of social sciences and law these faculties together award a range of academic degrees spanning bachelors and masters degrees as well as junior doctorates and higher doctorates university of bristol was established in  and is based in bristol united kingdom career history director  partner   current kuzari group llc kuzari group llc operates as a private investment and strategic development firm it focuses on investing in and developing small businesses which represents longterm value creation opportunities the company was founded by benjamin gerut in  and is headquartered in new york ny boards  committees corporate boards ▾ director   current precipio inc precipio inc engages in the development and provision of a platform designed to eradicate the problem of misdiagnosis the firm intends to invest in further development of its icp technology to define specific clinical applications as well as simplifying the adaptability and implementation of icp technology for its customers its products include technology suite mxicp iceme kits genetic assays and platforms the company is headquartered in omaha ne director  partner   current kuzari group llc kuzari group llc operates as a private investment and strategic development firm it focuses on investing in and developing small businesses which represents longterm value creation opportunities the company was founded by benjamin gerut in  and is headquartered in new york ny director current precipio diagnostics llc precipio diagnostics llc operates as a cancer diagnostics reference laboratory it offers its customers community oncologists and hospitals access to academic institutions and has combined academiclevel excellence with the sales and marketing expertise the proper operational processes and the necessary service level standards required to deliver proper support the company was founded by ilan danieli in  and is headquartered in new haven ct member board of directors   prior transgenomic inc transgenomic inc is a global biotechnology company which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and worldclass clinical and research services it operates through the following reportable segments laboratory services and genetic assays and platforms the laboratory services segment is a combination of clinical laboratories and pharmacogenomic services business segments the clinical laboratories segment specializes in genetic testing for cardiology neurology mitochondrial disorders and oncology the laboratory services segment also provides pharmacogenomics research services supporting phase ii and phase iii clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies including ice coldpcr technologythe genetic assay and platforms segment includes wave system product which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics this segment also manufactures and sells consumable products that can be used on multiple independent platforms these products include surveyor nuclease and a range of chromatography columns transgenomic was founded on march   and is headquartered in omaha ne public holdings restricted data only for relsci professional users start my free trial ➤ see more other affiliations mark rimer is affiliated with kuzari group llc precipio inc kuzari group llc precipio diagnostics llc transgenomic inc youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤